16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Development of a 'ready-to-use' tool that includes preventability, for the assessment of adverse drug events in oncology.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background Adverse drug events (ADEs) occur frequently in oncology and justify continuous assessment and monitoring. There are several methods for detecting them, but the trigger tool method seems the most appropriate. Although a generic tool exists, its use for ADEs in oncology has not been convincing. The development of a focused version is therefore necessary. Objective To provide an oncology-focused trigger tool that evaluates the prevalence, harm, and preventability in a standardised method for pragmatic use in ADE surveillance. Setting Hospitals with cancer care in France. Method The tool has been constructed in two steps: (1) constitution of an oncology-centred list of ADEs; 30 pharmacists/practitioners in cancer care from nine hospitals selected a list of ADEs using a method of agreement adapted from the RAND/UCLA Appropriateness Method; and (2) construction of three standardised dimensions for the characterisation of each ADE (including causality, severity, and preventability). Main outcome measure The main outcome measure was validation of the tool, including preventability criteria. Results The tool is composed of a final list of 15 ADEs. For each ADE, a 'reviewer form' has been designed and validated by the panel. It comprises (1) the trigger(s), (2) flowcharts to guide the reviewer, (3) criteria for grading harm, and (4) a standardised assessment of preventability with 6-14 closed sentences for each ADE in terms of therapeutic management and/or prevention of side-effects. Conclusion A complete 'ready-to-use' tool for ADE monitoring in oncology has been developed that allows the assessment of three standardised dimensions.

          Related collections

          Author and article information

          Journal
          Int J Clin Pharm
          International journal of clinical pharmacy
          Springer Science and Business Media LLC
          2210-7711
          Apr 2018
          : 40
          : 2
          Affiliations
          [1 ] Département de Pharmacie Clinique, Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France. guillaume.hebert@gustaveroussy.fr.
          [2 ] Research Team 'Management des Organisations de Santé' (EA 7348), École de Hautes Études en Santé Publique, 15 Avenue du Professeur Léon-Bernard, 35043, Rennes Cedex, France. guillaume.hebert@gustaveroussy.fr.
          [3 ] Département de Pharmacie Clinique, Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
          [4 ] Research Team 'Management des Organisations de Santé' (EA 7348), École de Hautes Études en Santé Publique, 15 Avenue du Professeur Léon-Bernard, 35043, Rennes Cedex, France.
          [5 ] Pharmacie Clinique, PRES Sorbonne Paris-Cité, Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006, Paris, France.
          [6 ] Mission 'Innovative Pathways', Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
          Article
          10.1007/s11096-017-0542-3
          10.1007/s11096-017-0542-3
          29446003
          f7043e65-7f33-4cd2-bb11-af13fa661886
          History

          Trigger tool,Preventability,Patient cancer care,Oncology,Healthcare quality,France,Adverse drug event

          Comments

          Comment on this article